Janssen’s Simponi Aria Gains Extended FDA Approvals for Rare Children’s Arthritis Conditions

The US Food and Drug Administration (FDA) has given approval to Janssen Pharmaceutical for Simponi Aria (golimumab) in the treatment of patients two years of age and older with active polyarticular juvenile idiopathic arthritis (pJIA). The regulator has also extended the active psoriatic arthritis (PsA) indication for the same patient population.